CAR-T cell therapy is being tested in prostate cancer research centers [77,78,79,80]; a recent report identifies 13 patients being treated with engineered CAR-T cells to target prostate-specific membrane antigens (PSMA) [78]. Here, FOLH1 is linked to prostate carcinoma.